Literature DB >> 1643724

Massive rhabdomyolysis and simvastatin.

N Bizzaro, E Bagolin, L Milani, C Cereser, B Finco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1643724

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  6 in total

1.  HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.

Authors:  E Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  Successful Treatment with Colesevelam HCl and Pravastatin in a Patient Previously Hospitalised with Severe Normal CPK Myopathy on Introduction of Simvastatin.

Authors:  John D Moore
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

3.  Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.

Authors:  Beatrice A Golomb; Abril Verden; Alexis K Messner; Hayley J Koslik; Keith B Hoffman
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

Review 4.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

5.  Peripheral neuropathy associated with simvastatin.

Authors:  T Phan; J G McLeod; J D Pollard; O Peiris; A Rohan; J P Halpern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-05       Impact factor: 10.154

6.  Are patients undergoing treatment of hyperlipidaemia with statins the best candidates for early cardiac rehabilitation?

Authors:  Rafał Celiński; Anna Grzywa-Celińska; Wojciech Myśliński; Andrzej Dybała; Jerzy Mosiewicz
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.